Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy

4 november 2010 uppdaterad av: Weill Medical College of Cornell University

The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy

The study will be conducted in two phases. Phase A will evaluate the contribution of bacterial overgrowth and colonic inertia to development of Hepatic Encephalopathy (HE)in 50 ambulatory subjects with HE and hepatitis C cirrhosis. This phase will include a Screening and Evaluation Visit.

Phase B will evaluate the effect of rifaximin on bacterial outgrowth and severity of HE in 20 of the subjects enrolled in Phase A who have a somewhat greater degree of encephalopathy.

The purpose of this study is to evaluate the following:

  1. the relationship between bacterial overgrowth and the presence and severity of HE in patients with hepatitis C cirrhosis;
  2. the effectiveness and tolerability of rifaximin relative to placebo in treatment of HE associated with hepatitis C cirrhosis;
  3. the relationship between bacterial overgrowth and the presence and severity of HE before and after rifaximin treatment.

Studieöversikt

Status

Okänd

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Hepatic encephalopathy is a frequent and occasionally refractory complication of cirrhosis and is associated with impaired quality of life. Its severity may not correlate with other parameters of liver dysfunction. Although multiple pathogenic mechanisms for the condition have been proposed, most include the participation of bacterial toxins, especially ammonia, produced in the gastrointestinal tract. Treatment options for hepatic encephalopathy at this time are limited to lactulose and neomycin. Lactulose is frequently poorly tolerated, and many patients are non-compliant with its use. In patients with renal insufficiency in whom hepatic encephalopathy is frequently problematic, use of neomycin is contraindicated due to ototoxicity and nephrotoxicity.

Autonomic dysfunction is common in patients with cirrhosis and could contribute to the development of hepatic encephalopathy by impairment of intestinal motility, leading to bacterial overgrowth and colonic inertia.

The following questions will be addressed:

A. Is impaired intestinal transit and bacterial overgrowth associated with the presence and severity of hepatic encephalopathy?

50 patients will undergo a detailed clinical evaluation for severity of liver disease, hepatic encephalopathy and assessment of intestinal transit and bacterial overgrowth with radiographic marker study and breath test analysis. Multivariate analysis will then be performed to determine the relationship of intestinal transit and evidence of bacterial overgrowth with the presence and severity of hepatic encephalopathy.

B. Does treatment with rifaximin improve bacterial overgrowth and hepatic encephalopathy?

20 patients from the above population with significant encephalopathy will be randomized to receive either rifaximin or placebo. Post-treatment evaluation for severity of hepatic encephalopathy and breath test analysis for bacterial overgrowth will then be performed. The effect of treatment on changes in hepatic encephalopathy and bacterial overgrowth and the relationship between changes in bacterial overgrowth and severity of hepatic encephalopathy will also be assessed.

Phase A Endpoints: Degree of bacterial overgrowth and its correlation with the grade of hepatic encephalopathy (if present).

Phase B Endpoints: To demonstrate improvement in degree of HE with treatment of Rifaximin

Efficacy Endpoints The primary efficacy endpoint for Phase B of the study will be the change from baseline in the proportion of patients with no HE, minimal HE (no symptoms, abnormal psychometric testing), mild persistent HE (mild symptoms), and persistent Stage II HE (presence of asterixis, history of hospitalization for spontaneous Stage III or IV HE).

Secondary efficacy endpoints for Phase B will be the following:

To demonstrate improvement in intestinal transit time for patients (based on Lactulose Hydrogen Breath Test) To demonstrate improvement in bacterial overgrowth, improved insomnia, flatulence, and quality of life.

To demonstrate that rifaximin improved patients' symptoms of insomnia, flatulence, and quality of life measure with the degree of bacterial overload and the impaired intestinal transit time.

Studietyp

Interventionell

Inskrivning (Förväntat)

50

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

  • Förenta staterna
    • New York
      • New York, New York, Förenta staterna, 10021
        • Rekrytering
        • New York Presbyterian Hospital: Weill Medical College of Cornell University
        • Kontakt:
        • Huvudutredare:
          • Sam Sigal, M.D.
        • Underutredare:
          • Brian P. Bosworth, M.D.
        • Underutredare:
          • Ilan Weisberg, M.D.

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Phase A Inclusion Criteria:

  • Subject is 18 to 70 years of age, inclusive.
  • Subject has cirrhosis due to chronic HCV infection as documented by:
  • Subject has evidence of hepatic encephalopathy as evidenced by:
  • Neuro-psychometric Testing (Number Connection Test, Trails Test, etc.)
  • Subject is non-azotemic (creatinine <1.5mg/dL) and ambulatory at screening.
  • Subject has cirrhosis due to chronic HCV as documented by: pathologic or clinical and radiographic evidence of cirrhosis with a positive HCV RNA PCR level.

Phase A Exclusion Criteria:

  • Subject has received active interferon therapy within 2 weeks of enrollment.
  • Subject is pregnant or lactating.
  • Subject has a life expectancy of less than 100 days.
  • Subject has a history of alcohol abuse within 6 months of enrollment.
  • Subject has active gastrointestinal bleeding at time of enrollment.
  • Subject has used an agent that alters intestinal motility, eg, methadone, cholestyramine, tricyclic antidepressants.
  • Subject is unable to take oral medication.
  • Subject has used neomycin or other antibiotic within 2 weeks of enrollment or is actively using lactulose at time of enrollment.
  • Subject is taking or has hypersensitivity or allergy to rifaximin or rifampin.
  • Subject requires long term antibiotic therapy (eg, Lyme Disease, tuberculosis).
  • Subject has known or suspected alcohol abuse or illicit drug use within 1 year of enrollment.
  • Subject has participated in an investigational drug or device study within the 30 days prior to randomization.
  • Subject has received rifaximin within the last 30 days.
  • Subject has concomitant disease or condition that could interfere with, or for which treatment could interfere with the conduct of the study, or could in the opinion of the investigator increase the risk of AEs for the subject's participation in the study.
  • Subject is unwilling or unable to comply with the study protocol for any other reason.
  • Subject has been diagnosed with other forms of liver disease, including those with HIV and HBV co-infection, as determined by history, serological parameters, and histology when available.
  • Subject has been diagnosed with a major psychiatric illness, chronic renal and/or respiratory insufficiency, intercurrent infections, treatment with sedatives within 7 days of enrollment.
  • Subject shows presence of intestinal obstruction or inflammatory bowel disease, antacids or cathartics within the 12h before study start; antibiotics during 7 days before start of dosing; or treated with encephalopathy-causing agents.
  • Subjects with bad vision or neurological diseases since they could have difficulty completing the neuropsychological assessments.

Phase B Inclusion Criteria

  • Subject successfully participated in and continues to meet all eligibility criteria required in Phase A of the study based on completion of tests, Breath Tests, and Radiological Marker.
  • Subject has a Number Connection Test score >50 sec at time of enrollment.

Phase B Exclusion Criteria

  • A subject will not be eligible for inclusion in Phase B if (s)he meets any of the exclusion criteria for Phase A of the study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Trippel

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Phase A: Degree of bacterial overgrowth and its correlation with the grade of hepatic encephalopathy (if present)
Tidsram: 3 months
3 months
Phase B: Improvement in the psychometric scores and proportion of patients who change of HE stage
Tidsram: 3 months
3 months

Sekundära resultatmått

Resultatmått
Tidsram
Improved Intestinal transit time
Tidsram: 3 months
3 months
Improvement in bacterial overgrowth
Tidsram: 3 months
3 months
Improved insomnia
Tidsram: 3 months
3 months
Improved flatulence
Tidsram: 3 months
3 months
Improved quality of life.
Tidsram: 3 months
3 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Weill Medical College of Cornell University

Samarbetspartners

Bausch Health Americas, Inc.

Utredare

  • Huvudutredare: Sam Sigal, M.D., Weill Medical College of Cornell University

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 december 2005

Primärt slutförande (Förväntat)

1 december 2012

Avslutad studie (Förväntat)

1 december 2012

Studieregistreringsdatum

Först inskickad

20 januari 2006

Först inskickad som uppfyllde QC-kriterierna

20 januari 2006

Första postat (Uppskatta)

24 januari 2006

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

5 november 2010

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

4 november 2010

Senast verifierad

1 november 2010

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • Salix-RifaxPSE-BactOvrGrwth-01

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Levercirros

Kliniska prövningar på Rifaximin (drug)

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Hong Kong

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera